Manal F. Abdelmalek, MD

Professor of Medicine
Campus mail 03119 Hosp South, Suite 03107, Room 03125, Durham, NC 27710
Phone (919) 684-3262
Email address manal.abdelmalek@duke.edu

My research interests include metabolic liver disease, particularly obesity-related liver disease and its association with complications of the insulin resistance syndrome. I am interested in studying the clinical, environmental, and genetic risk factors for nonalcoholic fatty liver disease, new therapeutic options for treatment, and evaluating the impact of NAFLD from a public health perspective.

In Their Words

Education and Training

  • Fellow in Gastroenterology, Medicine, Mayo School of Health Sciences, 1995 - 1998
  • Medical Resident, Medicine, Mayo School of Health Sciences, 1992 - 1995
  • M.D., University Missouri Kansas City, 1992

Publications

Glass, O, Henao, R, Patel, K, Guy, CD, Gruss, HJ, Syn, W-K, Moylan, CA, Streilein, R, Hall, R, Mae Diehl, A, and Abdelmalek, MF. "Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease." Hepatology Communications 2, no. 11 (November 2018): 1344-1355.

PMID
30411081
Full Text

Jayakumar, S, Middleton, MS, Lawitz, EJ, Mantry, PS, Caldwell, SH, Arnold, H, Mae Diehl, A, Ghalib, R, Elkhashab, M, Abdelmalek, MF, Kowdley, KV, Stephen Djedjos, C, Xu, R, Han, L, Mani Subramanian, G, Myers, RP, Goodman, ZD, Afdhal, NH, Charlton, MR, Sirlin, CB, and Loomba, R. "Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib." Journal of Hepatology (October 4, 2018).

PMID
30291868
Full Text

Abdelmalek, MF, Lanthier, N, Chojkier, M, Kluwe, J, Fowell, AJ, Yuan, J, Nicandro, JP, Seyedkazemi, S, Fischer, L, Goodman, ZD, and Harrison, SA. "Cenicriviroc Treatment over 2 Years Results in Clinically Meaningful and Sustained Improvement in Fibrosis in Adults with Nonalcoholic Steatohepatitis and Severe Liver Fibrosis." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Chaudhry, M, Moylan, CA, Middleton, MS, Farjat, A, Chaudhury, KR, Guy, CD, Abdelmalek, MF, Loomba, R, Sirlin, CB, and Bashir, M. "Quantifying the Placebo Effect on Liver Fat Using Magnetic Resonance Imaging-Proton Density Fat Fraction in NAFLD Clinical Trials." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Chaudhry, M, Moylan, CA, Middleton, MS, Farjat, A, Chaudhury, KR, Guy, CD, Abdelmalek, MF, Loomba, R, Sirlin, CB, and Bashir, M. "Quantifying the Placebo Effect on Liver Fat Using Magnetic Resonance Imaging-Proton Density Fat Fraction in NAFLD Clinical Trials." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Halegoua-De Marzio, D, Thuluvath, PJ, Abdelmalek, MF, Van Biene, C, Shringarpure, R, and MacConell, L. "Obeticholic Acid Was Safe and Well Tolerated in Patients with Nonalcoholic Steatohepatitis and Compensated Cirrhosis: A Secondary Analysis of the Control Study." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Halegoua-De Marzio, D, Thuluvath, PJ, Abdelmalek, MF, Van Biene, C, Shringarpure, R, and MacConell, L. "Obeticholic Acid Was Safe and Well Tolerated in Patients with Nonalcoholic Steatohepatitis and Compensated Cirrhosis: A Secondary Analysis of the Control Study." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Chalasani, NP, Lawitz, EJ, Abdelmalek, MF, Rinella, MEM, Harrison, SA, Sanyal, AJ, Noureddin, M, Rockey, DC, Ber, TI, Ilan, Y, Garcia-Tsao, G, and Traber, PG. "The Noninvasive Point of Care MBT Accurately Predicts Decompensation Events Better Than MELD in Compensated (MELD Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Chalasani, NP, Lawitz, EJ, Abdelmalek, MF, Rinella, MEM, Harrison, SA, Sanyal, AJ, Noureddin, M, Rockey, DC, Ber, TI, Ilan, Y, Garcia-Tsao, G, and Traber, PG. "The Noninvasive Point of Care MBT Accurately Predicts Decompensation Events Better Than MELD in Compensated (MELD Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Yang, JD, Abdelmalek, MF, Guy, CD, Diehl, AM, and Suzuki, A. "Reply." Clinical Gastroenterology and Hepatology 16, no. 10 (October 1, 2018): 1684-null. (Letter)

Full Text

Pages